Showing results (841-850 of 2,231) with videos related to
Sort By:
Pageof 224
Cancer Biotherapy & Radiopharmaceuticals|January 29, 2013
Activator protein-1 inhibition by 3-[(dodecylthiocarbonyl)methyl]-glutamaride impairs invasion and radiosensitizes osteosarcoma cells in vitroMaría Sol Brassesco, Julia Alejandra Pezuk, Jaqueline Carvalho de Oliveira, et al.Cancer Biotherapy & Radiopharmaceuticals|January 5, 2013
Penetratin-mediated delivery enhances the antitumor activity of the cationic antimicrobial peptide Magainin IIShan Liu, Hao Yang, Lin Wan, et al.Cancer Biotherapy & Radiopharmaceuticals|April 25, 2013
Practicality of production of ³²P by direct neutron activation for its utilization in bone pain palliation as Na₃[³²P]PO₄K V Vimalnath, Priyalata Shetty, Sudipta Chakraborty, et al.Cancer Biotherapy & Radiopharmaceuticals|May 25, 2013
Human prostate stem cell antigen and HSP70 fusion protein vaccine inhibits prostate stem cell antigen-expressing tumor growth in miceLei Dong, Xiaopeng Zhang, Jun Ren, et al.Cancer Biotherapy & Radiopharmaceuticals|May 28, 2013
CpG-ODN 7909 increases radiation sensitivity of radiation-resistant human lung adenocarcinoma cell line by overexpression of Toll-like receptor 9Li Yan, Guoxiong Xu, Tiankui Qiao, et al.Cancer Biotherapy & Radiopharmaceuticals|May 30, 2013
Detection of resectable recurrences in colorectal cancer patients with 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomographyNan-Jing Peng, Chin Hu, Tai-Ming King, et al.Cancer Biotherapy & Radiopharmaceuticals|June 18, 2013
NVP-BEZ235, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, prominently enhances radiosensitivity of prostate cancer cell line PC-3Wenjie Zhu, Weijiang Fu, Likuan HuCancer Biotherapy & Radiopharmaceuticals|June 20, 2013
Downregulated RhoBTB2 expression contributes to poor outcome in osteosarcoma patientsZhe Jin, Ya-Xin Han, Xiao-Rui HanCancer Biotherapy & Radiopharmaceuticals|July 13, 2013
Emerging trends for radioimmunotherapy in solid tumorsManeesh Jain, Suprit Gupta, Sukhwinder Kaur, et al.Cancer Biotherapy & Radiopharmaceuticals|March 28, 2013
Phase I study of a modified regimen of ⁹⁰Yttrium-ibritumomab tiuxetan for relapsed or refractory follicular or transformed CD20+ non-Hodgkin lymphomaChristos Vaklavas, Ruby F Meredith, Sui Shen, et al.Pageof 224